Login Register
icon_bulk_orderBulk order Acrobiosystems for English
0
There is no goods in the shopping cart !
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 0-9
Your Position: Home > LAG-3

LAG-3

Brief Information

Name:Lymphocyte activation gene 3 protein
Target Synonym:Lymphocyte activation gene 3 protein,LAG3,Lymphocyte Activating 3,Lymphocyte-Activation Gene 3,CD223 Antigen,Protein FDC,CD223,LAG-3,FDC,sLAG-3
Number of Launched Drugs:0
Number of Drugs in Clinical Trials:25
Lastest Research Phase:Phase 3 Clinical

Licensing

Project item Indications Research phase Cooperation demands
BMS21011 Tumors such as melanoma, non-small cell lung cancer,liver cancer, gastric carcinoma Cell line screening Project authorization, transfer or co-development. (project’s company is seeking for external cooperation to accelate drug research and development.)

Product ListCompare or Buy

Cat. No. Species Product Description Structure Purity Feature
LA3-H82E9 Human Biotinylated Human LAG-3 / CD223 Protein, His,Avitag™ (MALS verified)
LA3-H82E9-structure
LA3-H82E9-sds
LA3-C8258 Cynomolgus Biotinylated Cynomolgus LAG-3 / CD223 Protein, Mouse IgG2a Fc Tag, ultra sensitivity (primary amine labeling)
LA3-C8258-structure
LA3-C8258-sds
LA3-C52H7 Canine Canine LAG-3 / CD223 Protein, His Tag (MALS verified)
LA3-C52H7-structure
LA3-C52H7-sds
LA3-C82H3 Cynomolgus Cynomolgus LAG-3 / CD223 Protein, His Tag
LA3-C82H3-structure
LA3-C82H3-sds
LA3-C82E5 Cynomolgus Biotinylated Cynomolgus LAG-3 / CD223 Protein, His,Avitag™
LA3-C82E5-structure
LA3-C82E5-sds
LA3-M82E5 Mouse Biotinylated Mouse LAG-3 / CD223 Protein, His,Avitag™ (MALS verified)
LA3-M82E5-structure
LA3-M82E5-sds
LA3-H82Fb Human Biotinylated Human LAG-3 / CD223 Protein, Fc,Avitag™ (MALS verified)
LA3-H82Fb-structure
LA3-H82Fb-sds
LA3-H525c Human Human LAG-3 / CD223 Protein, Llama IgG2b Fc Tag, low endotoxin (MALS verified)
LA3-H525c-structure
LA3-H525c-sds
LA3-H522a Human Human LAG-3 / CD223 Protein, His Tag, low endotoxin
LA3-H522a-structure
LA3-H522a-sds
LA3-H82F3 Human Biotinylated Human LAG-3 / CD223 Protein, Mouse IgG2a Fc,Avitag™ (MALS verified)
LA3-H82F3-structure
LA3-H82F3-sds
LA3-M52Ha Marmoset Marmoset LAG-3 / CD223 Protein, His Tag
LA3-M52Ha-structure
LA3-M52Ha-sds
LA3-H52Aa Human Human LAG-3 / CD223 Protein, Mouse IgG2a Fc Tag (MALS verified)
LA3-H52Aa-structure
LA3-H52Aa-sds
LA3-C52A0 Cynomolgus Cynomolgus LAG-3 / CD223 Protein, Mouse IgG2a Fc Tag
LA3-C52A0-structure
LA3-C52A0-sds
LA3-C5252 Cynomolgus Cynomolgus LAG-3 / CD223 Protein, Fc Tag
LA3-C5252-structure
LA3-C5252-sds
LA3-H5255 Human Human LAG3 / CD223 Protein, Fc Tag (MALS Verified)
LA3-H5255-structure
LA3-H5255-sds
LA3-M52H5 Mouse Mouse LAG-3 / CD223 Protein, His Tag
LA3-M52H5-structure
LA3-M52H5-sds
LA3-R52H5 Rat Rat LAG3 / CD223 Protein, His Tag
LA3-R52H5-structure
LA3-R52H5-sds
LA3-H5222 Human Human LAG-3 / CD223 Protein, His Tag (MALS verified)
LA3-H5222-structure
LA3-H5222-sds

Part of Bioactivity data

LA3-H82F3-Cell-based assay
FACS assay shows that recombinant Biotinylated FACS

Flow Cytometry assay shows that Biotinylated Human LAG-3, Mouse IgG2a Fc,Avitag (Cat. No. LA3-H82F3) can bind to daudi cell surface. The concentration of LAG-3 used is 0.3 μg/mL (Routinely tested).

LA3-H52Aa-Cell-based assay
FACS assay shows that recombinant Biotinylated FACS

Flow Cytometry assay shows that Human LAG3, Mouse IgG2a Fc Tag (Cat. No. LA3-H52Aa) can bind to daudi cell surface. The concentration of LAG3 used is 0.3 μg/mL (Routinely tested).

LA3-H5222-SPR
Human_FcRn_Heterodimer_Protein_SPR

Anti-LAG-3 MAb (Human IgG1) captured on CM5 chip via Anti-Human IgG Fc antibodies surface, can bind Human LAG-3, His Tag (Cat. No. LA3-H5222) with an affinity constant of 4.57 nM as determined in a SPR assay (Biacore T200) (Routinely tested).

LA3-H5222-BLI
Human_FcRn_Heterodimer_Protein_Bli

Loaded Anti-LAG-3 MAb (Human IgG1) on AHC Biosensor, can bind Human LAG-3, His Tag (Cat. No. LA3-H5222) with an affinity constant of 7.47 nM as determined in BLI assay (ForteBio Octet Red96e) (Routinely tested).

Customer Reviews

Synonym Name

LAG3,CD223,FDC

Background

Lymphocyte activation gene 3 protein (LAG3) is also known as CD antigen CD223 and protein FDC, which belongs to immunoglobulin (Ig) superfamily and contains 4 extracellular Ig-like domains. The LAG3 gene contains 8 exons. The sequence data, exon/intron organization, and chromosomal localization all indicate a close relationship of LAG3 to CD4. LAG3 /CD223 involved in lymphocyte activation. LAG3 /CD223 binds to HLA class-II antigens.

Clinical and Translational Updates

Clinical Drug Information

Name Research Code Research Phase Company Indications Clinical Trials
Ieramilimab IMP-701; LAG-525 Phase 2 Clinical Immutep Ovarian Neoplasms; Hematologic Neoplasms; Solid tumours; Stomach Neoplasms; Lymphoma, Large B-Cell, Diffuse; Triple Negative Breast Neoplasms; Small Cell Lung Carcinoma; Prostatic Neoplasms, Castration-Resistant; Neuroendocrine Tumors; Sarcoma; Prostatic Neoplasms; Esophageal adenocarcinoma; Melanoma; Persistent Fetal Circulation Syndrome; Adenocarcinoma Details
DNV-3 DNV-3; DNV3 Phase 1 Clinical Zhejiang Shimai Pharmaceutical Co Ltd Solid tumours; Lymphoma Details
KL-A289 KL-A289 Phase 1 Clinical Sichuan Kelun-Biotech Biopharmaceutical Co Ltd Solid tumours Details
INCAGN-2385 INCAGN-2385; INCAGN-02385 Phase 2 Clinical Agenus Inc Melanoma Details
HLX-26 HLX-26 Phase 1 Clinical Shanghai Henlius Biologics Co Ltd Solid tumours; Lymphoma Details
Chlorogenic acid Phase 3 Clinical Sichuan JZ Bio-chemical Science and Technology Development Co Ltd Liver Neoplasms; Kidney Neoplasms; Adenocarcinoma of Lung; Glioblastoma; Glioma; Lung Neoplasms; Carcinoma, Non-Small-Cell Lung Details
LBL-007 LBL-007 Phase 2 Clinical Solid tumours; Lymphoma; Melanoma Details
FS 118 FS-118 Phase 2 Clinical Merck Serono, F-Star Hematologic Neoplasms; Squamous Cell Carcinoma of Head and Neck; Neoplasm Metastasis Details
ABL-501 ABL-501 Phase 1 Clinical Abl Bio Solid tumours Details
EMB-02 EMB-02 Phase 2 Clinical Shanghai Epimab Biotherapeutics, Inc Solid tumours Details
IBI-323(Innovent Biologics) IBI-323 Phase 1 Clinical Innovent Biologics(Suzhou) Co Ltd Solid tumours Details
Sym-022 Sym-022 Phase 1 Clinical Symphogen Solid tumours; Lymphoma; Neoplasm Metastasis Details
Encelimab TSR-033; TSR 033; TSR033; GSK-4074386 Phase 1 Clinical Anaptysbio Neoplasms Details
Miptenalimab BI-754111 Phase 2 Clinical C.H. Boehringer Sohn Ag & Co. Kg Head and Neck Neoplasms; Neoplasms; Carcinoma, Non-Small-Cell Lung; Neoplasm Metastasis Details
Fianlimab REGN-3767 Phase 1 Clinical Regeneron Pharmaceuticals Inc Neoplasms Details
Tebotelimab MGD-013; PD-1 X LAG-3 Phase 3 Clinical Macrogenics Small Cell Lung Carcinoma; Carcinoma, Non-Small-Cell Lung; Melanoma; Neoplasm Metastasis; Uterine Cervical Neoplasms; Carcinoma, Hepatocellular; Adenocarcinoma; Endometrial Neoplasms; Cholangiocarcinoma; Solid tumours; Triple Negative Breast Neoplasms; Squamous Cell Carcinoma of Head and Neck; Esophageal Neoplasms; Stomach Neoplasms; Hematologic Neoplasms; Ovarian Neoplasms; Head and Neck Neoplasms; Biliary Tract Neoplasms Details
Relatlimab BMS-986016; ONO-4482 Phase 3 Clinical Bristol-Myers Squibb Company Hematologic Neoplasms; Solid tumours; Stomach Neoplasms; Colorectal Neoplasms; Melanoma; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Large intestine neoplasm Details
Bavunalimab XmAb-22841; XmAb-841 Phase 1 Clinical Xencor Cholangiocarcinoma; Carcinoma, Non-Small-Cell Lung; Carcinoma, Hepatocellular; Melanoma; Uterine Cervical Neoplasms; Penile Neoplasms; Endometrial Neoplasms; Fallopian Tube Neoplasms; Colorectal Neoplasms; Peritoneal Neoplasms; Nasopharyngeal Carcinoma; Solid tumours; Prostatic Neoplasms; Carcinoma, Transitional Cell; Carcinoma, Ovarian Epithelial; Triple Negative Breast Neoplasms; Pancreatic Neoplasms; Small Cell Lung Carcinoma; Squamous Cell Carcinoma of Head and Neck; Esophageal Neoplasms; Stomach Neoplasms; Carcinoma, Renal Cell Details
IBI-110 IBI-110 Phase 2 Clinical Innovent Biologics(Suzhou) Co Ltd Hematologic Neoplasms; Squamous Cell Carcinoma of Head and Neck; Small Cell Lung Carcinoma; Lymphoma, Large B-Cell, Diffuse; Carcinoma, Small Cell; Carcinoma, Non-Small-Cell Lung Details
Nivolumab/Relatlimab BMS-936558/BMS-986016; BMS-986213 Phase 3 Clinical Bristol-Myers Squibb Company Solid tumours; Stomach Neoplasms; Esophageal Neoplasms; Melanoma Details
SHR-1802 SHR-1802 Phase 2 Clinical Suzhou Suncadia Biopharmaceuticals Co Ltd, Jiangsu Hengrui Medicine Co Ltd, Shanghai Hengrui Pharmaceutical Co Ltd Solid tumours Details
Eftilagimod alpha hLAG-3Ig; CD-223; EDP-202; EOC-202; IMP-321 Phase 2 Clinical Immutep, Prima Biomed Solid tumours; Squamous Cell Carcinoma of Head and Neck; Breast Neoplasms; Carcinoma, Squamous Cell; Carcinoma, Non-Small-Cell Lung; Adenocarcinoma; Melanoma Details
BMS-986416 BMS-986416 Phase 1 Clinical Bristol-Myers Squibb Company Solid tumours Details
Mavezelimab/Pembrolizumab MK-4280A Phase 3 Clinical Msd Ireland (Carlow) Merck Sharp & Dohme Corp, Moshadong R & D (China) Co Ltd Solid tumours; Carcinoma, Renal Cell; Colorectal Neoplasms; Carcinoma, Non-Small-Cell Lung Details
Mavezelimab MK-4280 Phase 2 Clinical Merck Sharp & Dohme Corp Lymphoma, B-Cell; Carcinoma, Renal Cell; Small Cell Lung Carcinoma; Hodgkin Disease; Lymphoma, Non-Hodgkin; Carcinoma, Non-Small-Cell Lung Details
RO-7247669 RO-7247669 Phase 2 Clinical F. Hoffmann-La Roche Ltd Solid tumours; Liver Neoplasms; Esophageal Squamous Cell Carcinoma; Melanoma; Carcinoma, Non-Small-Cell Lung Details

This web search service is supported by Google Inc.

totop
Call us
Call us
North America: +1 800-810-0816 (Toll Free)
Asia & Pacific: +86 400-682-2521
Fax
Fax
+1 888-377-6111
Address
Address
1 Innovation Way, Newark, DE 19711, USA

Leave a message